Ke, Tao, Jiye Wang, Erik R. Swenson, Xiangnan Zhang, Yunlong Hu, Yaoming Chen, Mingchao Liu, Wenbin Zhang, Feng Zhao, Xuefeng Shen, Qun Yang, Jingyuan Chen, and Wenjing Luo. Effect of acetazolamide and gingko biloba on the human pulmonary vascular response to an acute altitude ascent. High Alt Med Biol 14:162–167, 2013.—Acetazolamide and gingko biloba are the two most investigated drugs for the prevention of acute mountain sickness (AMS). Evidence suggests that they may also reduce pulmonary artery systolic pressure (PASP). To investigate whether these two drugs for AMS prevention also reduce PASP with rapid airlift ascent to high altitude, a randomized controlled trial was conducted on 28 healthy young men with acetazolamide (125 mg bid), gingko biloba (120 mg bid), or placebo for 3 days prior to airlift ascent (397 m) and for the first 3 days at high altitude (3658 m). PASP, AMS, arterial oxygen saturation (Sao2), mean arterial pressure (MAP), heart rate (HR), forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), and peak expiratory flow (PEF) were assessed both at 397 m and 3658 m. HR, PEF, and PASP increased with altitude exposure (p<0.05), and SaO2 decreased (p<0.05). PASP with acetazolamide (mean at 3658 m, 26.2 mm Hg; incremental change, 4.7 mm Hg, 95% CI., 2.6–6.9 mm Hg) was lower than that with ginkgo biloba (mean at 3658 m, 33.7 mm Hg, p=0.001; incremental change, 13.1 mm Hg, 95%CI., 9.6–16.5 mm Hg, p=0.002), and with placebo (mean at 3658 m, 34.7 mm Hg, p<0.001; 14.4 mm Hg, 95% CI., 8.8–20.0 mm Hg, p=0.001). The data show that a low prophylactic dosage of acetazolamide, but not gingko biloba, mitigates the early increase of PASP in a quick ascent profile.
Get full access to this article
View all access options for this article.
References
1.
AllemannY, SartoriC, LeporiM, PierreS, MélotC, NaeijeR, ScherrerU, MaggioriniM. 2000. Echocardiographic and invasive measurements of pulmonary artery pressure correlate closely at high altitude. Am J Physiol Heart Circ Physiol, 279:H2013–2016.
2.
BalanosGM, TalbotNP, DorringtonKL, RobbinsPA. 2003. Human pulmonary vascular response to 4 h of hypercapnia and hypocapnia measured using Doppler echocardiography. J Appl Physiol, 94:1543–1551.
BasnyatB, GertschJH, HolckPS, JohnsonEW, LuksAM, DonhamBP, FleischmanRJ, GowderDW, HawksworthJS, JensenBT, KleimanRJ, LoveridgeAH, LundeenEB, NewmanSL, NoboaJA, MiegsDP, O'BeirneKA, PhilpotKB, SchultzMN, ValenteMC, WiebersMR, SwensonER. 2006. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: The prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol, 7:17–27.
5.
BasnyatB, GertschJH, JohnsonEW, Castro-MarinF, InoueY, YehC. 2003. Efficacy of low-dose acetazolamide (125 mg BID) for the prophylaxis of acute mountain sickness: A prospective, double-blind, randomized, placebo-controlled trial. High Alt Med Biol, 4:45–52.
6.
BasnyatB, HargroveJ, HolckPS, SrivastavS, AlekhK, GhimireLV, PandeyK, GriffithsA, ShankarR, KaulK, PaudyalA, StasiukD, BasnyatR, DavisC, SouthardA, RobinsonC, ShandleyT, JohnsonDW, ZafrenK, WilliamsS, WeissEA, FarrarJJ, SwensonER. 2008. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol, 9:209–216.
EmeryCJ, SloanPJ, MohammedFH, BarerGR. 1977. The action of hypercapnia during hypoxia on pulmonary vessels. Bull Eur Physiopathol Respir, 13:763–776.
12.
FaoroV, HuezS, GiltaireS, PavelescuA, van OstaA, MoraineJJ, GuenardH, MartinotJB, NaeijeR. 2007. Effects of acetazolamide on aerobic exercise capacity and pulmonary hemodynamics at high altitudes. J Appl Physiol, 103:1161–1165.
13.
GrünigE, MerelesD, HildebrandtW, SwensonER, KüblerW, KuechererH, BärtschP. 2000. Stress Doppler echocardiography for identification of susceptibility to high altitude pulmonary edema. J Am Coll Cardiol, 35:980–987.
HohneC, PickerodtPA, FrancisRC, BoemkeW, SwensonER. 2007. Pulmonary vasodilation by acetazolamide during hypoxia is unrelated to carbonic anhydrase inhibition. Am J Physiol Lung Cell Mol Physiol, 292:L178–184.
16.
HopkinsSR, GargJ, BolarDS, BalouchJ, LevinDL. 2005. Pulmonary blood flow heterogeneity during hypoxia and high-altitude pulmonary edema. Am J Respir Crit Care Med, 171:83–87.
17.
KawashimaA, KuboK, MatsuzawaY, KobayashiT, SekiguchiM. 1992. Hypoxia-induced ANP secretion in subjects susceptible to high-altitude pulmonary edema. Respir Physiol, 89:309–317.
18.
MaggioriniM. 2006. High altitude-induced pulmonary oedema. Cardiovasc Res, 72:41–50.
19.
MaggioriniM, Brunner-La RoccaHP, PethS, FischlerM, BöhmT, BernheimA, KienckeS, BlochKE, DehnertC, NaeijeR, LehmannT, BärtschP, MairbäurlH. 2006. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med, 145:497–506.
20.
MaggioriniM, MélotC, PierreS, PfeifferF, GreveI, SartoriC, LeporiM, HauserM, ScherrerU, NaeijeR. 2001. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation, 103:2078–2083.
21.
MoviatM, PickkersP, van der VoortPH, van der HoevenJG. 2006. Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients. Crit Care, 10:R14.
22.
PeacockAJ, ChallenorV, SutherlandG. 1990. Estimation of pulmonary artery pressure by Doppler echocardiography in normal subjects made hypoxic. Respir Med, 84:335–337.
23.
RenDC, DuGH, ZhangJT. 2002. Protective effect of ginkgo biloba extract on endothelial cell against damage induced by oxidative stress. J Cardiovasc Pharmacol, 40:809–814.
24.
RichaletJP, GratadourP, RobachP, PhamI, DéchauxM, Joncquiert-LatarjetA, MollardP, BrugniauxJ, CornoloJ. 2005. Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. Am J Respir Crit Care Med, 171:275–281.
25.
RichaletJP, RiveraM, BouchetP, ChirinosE, OnnenI, PetitjeanO, BienvenuA, LasneF, MoutereauS, León-VelardeF. 2005. Acetazolamide: a treatment for chronic mountain sickness. Am J Respir Crit Care Med, 172:1427–1433.
26.
Roach RCBP, HackettPH, OelzO. 1993. The Lake Louise Acute Mountain Sickness Scoring System. Hypoxia and Molecular Medicine: Proceedings of the 8th International Hypoxia Symposium, Lake Louise, Alberta, CanadaSuttonJR, CoatesG, HoustonCS. Burlington, Vt: Queen City Printers.
27.
ShimodaLA, LukeT, SylvesterJT, ShihHW, JainA, SwensonER. 2007. Inhibition of hypoxia-induced calcium responses in pulmonary arterial smooth muscle by acetazolamide is independent of carbonic anhydrase inhibition. Am J Physiol Lung Cell Mol Physiol, 292:L1002–1012.
28.
SwensonER, MaggioriniM, MongovinS, GibbsJS, GreveI, MairbäurlH, BärtschP. 2002. Pathogenesis of high-altitude pulmonary edema: Inflammation is not an etiologic factor. JAMA, 287:2228–2235.
29.
TeppemaLJ, BalanosGM, SteinbackCD, BrownAD, FosterGE, DuffHJ, LeighR, PoulinMJ. 2007. Effects of acetazolamide on ventilatory, cerebrovascular, and pulmonary vascular responses to hypoxia. Am J Respir Crit Care Med, 175:277–281.
30.
Tissot van PatotMC, LeadbetterG3rd, KeyesLE, MaakestadKM, OlsonS, HackettPH. 2008. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol, 9:289–293.
31.
WuYZ, LiSQ, ZuXG, DuJ, WangFF. 2008. Ginkgo biloba extract improves coronary artery circulation in patients with coronary artery disease: Contribution of plasma nitric oxide and endothelin-1. Phytother Res, 22:734–739.
32.
YockPG, PoppRL. 1984. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation, 70:657–662.
